Consortium provide €100m for Symphogen

The company has previously completed a number of funding rounds from investors such as Novo, Essex Woodlands, Vækstfonden, Scandinavian Life Science Ventures, Sunstone Capital and Gilde Healthcare Partners. The recent funding round will accelerate the advancement of the company's lead clinical oncology product.

Novo and Essex Woodlands are providing 70% of the investment with the remainder provided by PKA. Essex is providing equity for the transaction through its Essex Woodlands Fund VIII.

Founded in 2000 and headquartered in Copenhagen, Symphogen is a biotechnology company specialising in therapeutic products based on natural human antibodies for the treatment and prevention of human disease.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Viktor Lundvall on +44 20 7004 7476 or viktor.lundvall@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Early-stage
• Denmark